Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Multi-omic analysis in injured humans: Patterns align with outcomes and treatment responses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Altered brown fat thermoregulation and enhanced cold-induced thermogenesis in young, healthy, winter-swimming men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Drug use in patients with short bowel syndrome and intestinal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Long-acting amylin analogues for the management of obesity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

The gastric hormone ghrelin stimulates food intake and increases plasma glucose through activation of the growth hormone secretagogue receptor (GHSR). Liver-expressed antimicrobial peptide 2 (LEAP2) has been proposed to inhibit actions of ghrelin through inverse effects on GHSR activity. Here, we investigate the effects of exogenous LEAP2 on postprandial glucose metabolism and ad libitum food intake in a randomized, double-blind, placebo-controlled, crossover trial of 20 healthy men. We report that LEAP2 infusion lowers postprandial plasma glucose and growth hormone concentrations and decreases food intake during an ad libitum meal test. In wild-type mice, plasma glucose and food intake are reduced by LEAP2 dosing, but not in GHSR-null mice, pointing to GHSR as a potential mediator of LEAP2's glucoregulatory and appetite-suppressing effects in mice.

OriginalsprogEngelsk
Artikelnummer100582
TidsskriftCell reports. Medicine
Vol/bind3
Udgave nummer4
Sider (fra-til)100582
ISSN2666-3791
DOI
StatusUdgivet - 19 apr. 2022

Bibliografisk note

© 2022 The Author(s).

ID: 77661398